61,200 Shares in Roivant Sciences Ltd. $ROIV Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 61,200 shares of the company’s stock, valued at approximately $2,166,000.

Several other large investors also recently bought and sold shares of ROIV. Allspring Global Investments Holdings LLC acquired a new stake in shares of Roivant Sciences during the first quarter worth about $3,957,000. Bank of America Corp DE boosted its position in shares of Roivant Sciences by 8.0% in the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock valued at $87,638,000 after purchasing an additional 235,493 shares during the period. Baader Bank Aktiengesellschaft acquired a new stake in shares of Roivant Sciences in the 4th quarter valued at about $1,029,000. Jefferies Financial Group Inc. purchased a new position in Roivant Sciences during the 4th quarter worth approximately $76,272,000. Finally, Nicholas Investment Partners LP grew its stake in Roivant Sciences by 13.9% during the 4th quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock worth $6,073,000 after buying an additional 34,235 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant’s Pulmovant reported positive Phase 2 results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The treatment produced a reported 56.3% placebo-adjusted reduction in pulmonary vascular resistance, and Roivant has begun the Phase 3 PHrontier trial. The results strengthen the case for a potentially important new therapy and were the primary reason for the recent rally. Roivant Reports Positive Mosliciguat Phase 2 Results
• Positive Sentiment: Jefferies raised its price target for ROIV to $52 from its prior target, while H.C. Wainwright increased its target to $47. The revisions signal continued analyst confidence following the mosliciguat data. Jefferies Raises Roivant Price Target H.C. Wainwright Raises Roivant Price Target
• Positive Sentiment: Large call-option activity and reports that hedge-fund ownership rose 41% in the second quarter indicate strong investor interest and bullish positioning, although options activity can also increase volatility. Roivant Call Option Activity
• Neutral Sentiment: Roivant presented at Citigroup’s Biopharma Back to School Summit and the Cantor Fitzgerald Global Healthcare Conference. These events may provide additional pipeline commentary, but the available reports do not identify a new material announcement. Citigroup Summit Transcript
• Negative Sentiment: The stock’s retreat appears to reflect profit-taking after reaching a record high near $42.50, rather than a clearly negative company-specific announcement. Roivant remains loss-making, and its valuation leaves the shares sensitive to clinical-trial execution and future regulatory risk.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Citigroup raised their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. TD Cowen upped their price target on shares of Roivant Sciences from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, UBS Group set a $55.00 price target on shares of Roivant Sciences in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and an average target price of $40.62.

Roivant Sciences Stock Performance

Shares of ROIV opened at $40.94 on Friday. The stock has a market capitalization of $29.57 billion, a P/E ratio of -77.25 and a beta of 1.12. Roivant Sciences Ltd. has a 1 year low of $13.81 and a 1 year high of $42.50. The company’s fifty day moving average is $35.68 and its two-hundred day moving average is $31.56.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The company had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Sell-side analysts predict that Roivant Sciences Ltd. will post -2 EPS for the current year.

Insider Activity

In related news, insider Mayukh Sukhatme sold 144,756 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $36.48, for a total value of $5,280,698.88. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at $679,649,358.72. This trade represents a 0.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00. Following the completion of the sale, the chief executive officer directly owned 1,599,154 shares in the company, valued at $57,201,738.58. This represents a 11.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,055,913 shares of company stock worth $107,261,258 in the last three months. 8.80% of the stock is currently owned by company insiders.

Roivant Sciences Profile

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.